The 3 Biggest Near-Term Risks That Inovio Faces
Inovio Pharmaceuticals (NASDAQ: INO) has enjoyed a remarkable year so far by any standard. The biotech is in the thick of the race to develop a COVID-19 vaccine. It has made significant progress with its other pipeline candidates. Inovio's shares have skyrocketed close to 350%. The biotech even ranks among the top 100 most popular stocks (and one of the top 3 most popular coronavirus stocks) on the fast-growing Robinhood trading platform.
But while Inovio has indeed deservedly received a lot of attention in 2020, its future remains uncertain. A lot could happen to derail the company's fast track to success. Here are the three biggest risks that Inovio faces in the near term.
Image source: Getty Images.
Source Fool.com
